#USA #Pittsburgh #Frost & Sullivan #MolecuLight #Wound Imaging

MolecuLight: A Leader in Wound Imaging

On October 28, 2026, MolecuLight, a notable player in the medical imaging sector, was awarded the Frost & Sullivan Global Company of the Year title for its remarkable contributions to wound imaging. This accolade underscores MolecuLight's integral role in advancing objective wound assessment, clinical evidence supporting improved patient outcomes, and its dedicated customer service program.

Recognition Highlights

The Frost & Sullivan award specifically recognizes MolecuLight’s innovative delivery of integrated portable imaging solutions. These groundbreaking technologies include:

• - Fluorescence imaging for bacterial visualization, including its location and load.
• - Digital wound measurement for precise evaluations.
• - Thermography to aid in detailed assessments.

Clinical professionals utilizing these tools can effectively identify elevated bacterial loads that may not be seen through visual examinations, closely monitor changes in wound size, and make well-informed treatment decisions. Additionally, the devices align with electronic health record (EHR) systems, ensuring efficient documentation and continuity of care.

MolecuLight's achievements are bolstered by its adherence to security standards, exemplified by its SOC 2 Type II and FIPS certifications, thereby reinforcing its commitment to safeguarding clinical documentation and establishing robust cybersecurity measures.

Clinical Evidence and Outcomes

The award further highlights the substantial clinical evidence supporting enhanced wound healing, reduced antibiotic usage, and fewer infectious complications due to fluorescence-guided care. MolecuLight is devoted to equipping clinical teams with efficient technology use, ensuring optimal patient outcomes.

According to Anil Amlani, CEO of MolecuLight, “This recognition continues our commitment to delivering clinical professionals the objective information necessary for better management of wound patients. By combining clinically validated imaging with practical workflows, training, and ongoing support, we empower care teams to translate information into therapeutic decisions that promote better healing.”

The Assessment Process

The 'Company of the Year' recognition by Frost & Sullivan evaluates organizations on innovation, performance, and customer impact. This reflects a rigorous analytical process undertaken by experts, assessing performance through comprehensive interviews, in-depth analyses, and extensive secondary research. The aim is to spotlight organizations that showcase exceptional achievements and set new standards within their industries.

About MolecuLight

MolecuLight is a privately held medical imaging diagnostics company recognized globally for manufacturing and marketing point-of-care diagnostic imaging devices for wounds. The company's FDA-cleared systems, MolecuLight iX® and MolecuLight DX®, enable real-time detection of high bacterial loads along with accurate digital wound measurement. The MolecuLight DX+® also incorporates thermal imaging capabilities. This technology has been validated through over 100 peer-reviewed publications.

About Frost & Sullivan

Frost & Sullivan has established itself as a leader in recognizing best practices across various sectors, highlighting companies that demonstrate innovation, customer experience excellence, and strategic product development. The awards serve as a benchmark of performance and growth, revealing organizations that spearhead transformative growth and establish new industry standards.

For further inquiries about MolecuLight’s award or its products, please reach out to Danielle Dunham, Product and Marketing Director. Visit their official website for more information and resources.